{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:06:15Z","timestamp":1761743175769},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1998,6,1]],"date-time":"1998-06-01T00:00:00Z","timestamp":896659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[1998,6]]},"DOI":"10.4065\/73.6.590","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:12:51Z","timestamp":1232759571000},"page":"590-596","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacologic Therapy for Prostatism"],"prefix":"10.4065","volume":"73","author":[{"given":"Michael M.","family":"Lieber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/73.6.590_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/archinte.1995.00430050053006","article-title":"New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States","volume":"155","author":"Jacobsen","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.4065\/73.6.590_bib2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0140-6736(95)91085-9","article-title":"Randomised, placebo-controlled, double-blind clinical trial of \u03b2-sitosterol in patients with benign prostatic hyperplasia","volume":"345","author":"Berges","year":"1995","journal-title":"Lancet"},{"key":"10.4065\/73.6.590_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1097-0045(199610)29:4<231::AID-PROS4>3.0.CO;2-E","article-title":"Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients","volume":"29","author":"Carraro","year":"1996","journal-title":"Prostate"},{"key":"10.4065\/73.6.590_bib4","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0090-4295(81)90071-6","article-title":"Phenoxybenzamine for benign pros-tatic obstruction: review of 200 cases","volume":"17","author":"Caine","year":"1981","journal-title":"Urology"},{"key":"10.4065\/73.6.590_bib5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/00003495-199652060-00012","article-title":"Tamsulosin: a review of its pharmacological properties and therapeutic potential in the management of symptom-atic benign prostatic hyperplasia","volume":"52","author":"Wilde","year":"1996","journal-title":"Drugs"},{"key":"10.4065\/73.6.590_bib6","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0022-5347(17)36941-0","article-title":"A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia","volume":"148","author":"Lepor","year":"1992","journal-title":"J Urol"},{"key":"10.4065\/73.6.590_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/archfami.2.9.929","article-title":"Terazosin in the treatment of benign prostatic hyperplasia","volume":"2","author":"Brawer","year":"1993","journal-title":"Arch Fam Med"},{"key":"10.4065\/73.6.590_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-5347(01)67243-4","article-title":"Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study","volume":"154","author":"Gillenwater","year":"1995","journal-title":"J Urol"},{"key":"10.4065\/73.6.590_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-5347(01)67240-9","article-title":"Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study","volume":"154","author":"Fawzy","year":"1995","journal-title":"J Urol"},{"key":"10.4065\/73.6.590_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000474321","article-title":"Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia: analysis of 5 studies","volume":"24","author":"Janknegt","year":"1993","journal-title":"Eur Urol"},{"key":"10.4065\/73.6.590_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000475055","article-title":"Terazosin and doxazosin in normo-tensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety","volume":"28","author":"Kaplan","year":"1995","journal-title":"Eur Urol"},{"key":"10.4065\/73.6.590_bib12","first-page":"145","article-title":"Tamsulosin, the first prostate-selective alA-adrenoceptor antagonist: analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symp-tomatic BPH)","volume":"29","author":"Schulman","year":"1996","journal-title":"Eur Urol"},{"issue":"Suppl","key":"10.4065\/73.6.590_bib13","first-page":"585A","article-title":"Long-term evaluation of tamsulosin, a prostate selective alphaj antagonist [abstract]","volume":"155","author":"Lepor","year":"1996","journal-title":"J Urol"},{"key":"10.4065\/73.6.590_bib14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1126\/science.186.4170.1213","article-title":"Steroid 5a-reductase deficiency in man: an inherited form of male pseudo-hermaphroditism","volume":"186","author":"Imperato-McGinley","year":"1974","journal-title":"Science"},{"key":"10.4065\/73.6.590_bib15","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199210223271701","article-title":"The effect of finasteride in men with benign prostatic hyperplasia","volume":"327","author":"Gormley","year":"1992","journal-title":"N Engl J Med"},{"key":"10.4065\/73.6.590_bib16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia","volume":"335","author":"Lepor","year":"1996","journal-title":"W Engl J Med"},{"key":"10.4065\/73.6.590_bib17","first-page":"1251","article-title":"Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year random-ized controlled trial (the PROSPECT Study)","volume":"155","author":"Nickel","year":"1996","journal-title":"Can Med Assoc J"},{"key":"10.4065\/73.6.590_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0090-4295(99)80291-X","article-title":"(Scandinavian BPH Study Group). Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-con-trolled study","volume":"46","author":"Andersen","year":"1995","journal-title":"Urology"},{"key":"10.4065\/73.6.590_bib19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0090-4295(96)00353-6","article-title":"Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials","volume":"48","author":"Boyle","year":"1996","journal-title":"Urology"},{"key":"10.4065\/73.6.590_bib20","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0090-4295(97)00185-4","article-title":"Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia","volume":"49","author":"Andersen","year":"1997","journal-title":"Urology"},{"key":"10.4065\/73.6.590_bib21","first-page":"326","article-title":"The effects of oral finasteride on scalp hair growth in men with male pattern baldness [abstract]","volume":"77","author":"Kaufman","year":"1995","journal-title":"Endocr Soc Annu Meet Program Abstr"},{"key":"10.4065\/73.6.590_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia","volume":"338","author":"McConnell","year":"1998","journal-title":"N Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611635283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611635283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T13:54:08Z","timestamp":1558101248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611635283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["S0025619611635283"],"URL":"https:\/\/doi.org\/10.4065\/73.6.590","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}